Fridays vs ShedRx vs SkinnyRx (2026)

On tirzepatide, the order is ShedRx↗ ($289) → SkinnyRx↗ ($299) → Fridays ($359) — gaps of $10 and then $60 a month, a $840 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

ShedRx: the record, condensed

ShedRx’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The structure is tiered: the advertised entry point is $199, but the maintenance figure — the one a full year is actually billed at — is $289. That $90 gap between the ad and the anniversary is the single most important line in this record.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #5 of 17 in the verified tirzepatide index — $74/month above the floor (NexLife↗, $215) — and sits $160 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,468.

ShedRx’s semaglutide program bills $249 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Note the shape: $175 is the number in the marketing, $249 is the number at maintenance. The $74 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

There is no membership line. $249 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #13 of 20 verified programs, with the floor $116/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $100 a month. A year at this figure: $2,988 monthly-billed.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

SkinnyRx: the record, condensed

SkinnyRx’s tirzepatide program bills $299 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #7 of 17 in the verified tirzepatide index — $84/month above the floor (NexLife, $215) — and sits $150 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,588.

SkinnyRx’s semaglutide program bills $199 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #11 of 20 verified programs, with the floor $66/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $150 a month. A year at this figure: $2,388 monthly-billed.

Operationally at SkinnyRx: shipping included; commitment none; cancellation no membership on compounded programs; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the SkinnyRx page · visit SkinnyRx ↗

Fridays: the record, condensed

On tirzepatide, the number that matters at Fridays is $359 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $359 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #13 of 17 verified programs, with the floor $144/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $90 a month. A year at this figure: $4,308 monthly-billed.

Start with the load-bearing figure: $175 a month, all-in, is what Fridays charges for semaglutide at the 2.4 mg basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Fridays is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #7 of 20 in the verified semaglutide index — $42/month above the floor (Oak Longevity, $133) — and sits $174 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,100.

Operationally at Fridays: shipping included; commitment annual plan for lowest rate; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Fridays page · visit Fridays ↗

§ The three-way read

Prices, gaps, and what sits inside them

ShedRx holds the low ground at $289 with no membership attached. SkinnyRx follows at $299 (+$10/mo, $120/yr). Fridays tops the trio at $359 (+$70/mo over the leader, $840/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles the order: Fridays $175 → SkinnyRx $199 → ShedRx $249 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: ShedRx ($289); cheapest 12-month path: ShedRx ($3,468); dose-flat structure: SkinnyRx and Fridays; cheapest semaglutide of the three: Fridays ($175).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: ShedRx vs SkinnyRx · ShedRx vs Fridays · SkinnyRx vs Fridays.

§ Structure, three ways

Everything besides the three prices

Memberships: ShedRx none; SkinnyRx none; Fridays none. Structures: ShedRx step/tiered; SkinnyRx dose-flat; Fridays dose-flat. Pharmacies: ShedRx not named; SkinnyRx not named; Fridays not named. States: ShedRx — not published; SkinnyRx — not published; Fridays — not published. Exit terms: ShedRx — 72-hour notice before the next billing cycle; SkinnyRx — no membership on compounded programs; Fridays — not published.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: ShedRx source-verified (2026-08-05); SkinnyRx source-verified (2026-08-05); Fridays third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: Fridays $525 vs SkinnyRx $597 vs ShedRx $747 6 mo: Fridays $1,050 vs SkinnyRx $1,194 vs ShedRx $1,494 12 mo: Fridays $2,100 vs SkinnyRx $2,388 vs ShedRx $2,988 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

ShedRx: $3,468/yr monthly-billed; SkinnyRx: $3,588/yr monthly-billed; Fridays: $4,308/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $1,680 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

Work it as eliminations rather than a beauty contest. Fridays enters owing an explanation: $70/month above ShedRx compounds to $840 a year — real therapy-months of money — so its record has to name what the premium buys (structure the cheaper two lack) or it exits first. SkinnyRx survives the first cut only to face the harder question — whether its dose-flat structure removes titration repricing is worth $10 a month to you — because a middle option that cannot answer it is just the expensive option with better camouflage. ShedRx is what remains: the arithmetic answer at $289, dethroned only by a state gap, a structural need, or a prescriber’s judgment — the three things this page deliberately cannot decide.

The same trio on best published rate: ShedRx $289 → SkinnyRx $299 → Fridays $359 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — ShedRx $867, SkinnyRx $897, Fridays $1,077; 6 months — ShedRx $1,734, SkinnyRx $1,794, Fridays $2,154. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

Grade the three records before trusting the three prices. On the five-point disclosure checklist (price, pharmacy, states, cancellation, source-verification): ShedRx 4/5 · SkinnyRx 4/5 · Fridays 3/5. The gap between ShedRx (4/5) and Fridays (3/5) is itself information: undisclosed axes are where the questions in each provider’s review earn their keep. No axis splits them, a small collective credit. Every score is a computation from the dataset, contestable at the corrections desk like any other figure.

The three-way verdict compresses cleanly: ShedRx is the default on arithmetic; SkinnyRx earns the middle only where its structure (flat pricing) solves something the floor does not; and Fridays’s $70/month premium over the leader — $840 a year, roughly 2.9 extra months of therapy at the floor rate — needs a named justification from its record, not a vibe. Insurance coverage, where it exists, outranks all three.